Incidence of thromboembolic complications in patients with atrial fibrillation or mechanical heart valves with a subtherapeutic international normalized ratio: A prospective multicenter cohort study

American Journal of Hematology

Volumn 87, Issue 4, 2012, Pages 384-387

  Dentali, Francesco ^a   Pignatelli, Pasquale ^b   Malato, Alessandra ^c   Poli, Daniela ^d   Minno, Matteo Nicola Dario Di ^e   Gennaro, Leonardo di ^f   Rancan, Elena ^a   Pastori, Daniele ^b   Grifoni, Elena ^d   Squizzato, Alessandro ^a   Siragusa, Sergio ^c   Minno, Giovanni di ^e   Ageno, Walter ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

^d Thrombosis Centre   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART VALVE PROSTHESIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTHETIC VALVE THROMBOSIS; STROKE; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TRANSIENT ISCHEMIC ATTACK;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; COMORBIDITY; FEMALE; FOLLOW-UP STUDIES; HEART VALVE PROSTHESIS; HEART VALVE PROSTHESIS IMPLANTATION; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RISK; THROMBOEMBOLISM; THROMBOPHILIA; WARFARIN;

EID: 84858280693     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23119     Document Type: Article

References (20)

1. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American college of chest physicians evidence-based clinical practice guidelines (8th ed). Chest 2008; 133: 454S-545S.
2. Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation. Circulation 2006; 114: e257-e354.
3. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American college of chest physicians evidence-based clinical practice guidelines (8th ed). Chest 2008; 133: 546S-592S.
4. Salem DN, O'Gara PT, Madias C, Pauker SG. Valvular and structural heart disease: American college of chest physicians evidence-based clinical practice guidelines (8th ed). Chest 2008; 133: 593S-629S.
5. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American college of chest physicians evidence-based clinical practice guidelines (8th ed). Chest 2008; 133: 160S-198S.
6. van Walraven C, Jennings A, Oake N, et al. Effect of study setting on anticoagulation control: A systematic review and metaregression. Chest 2006; 129: 1155-1166.
7. White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: Results from SPORTIF III and V. Arch Intern Med 2007; 167: 239-245.
8. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105: 91-99.
9. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: An inceptioncohort, prospective collaborative study (ISCOAT). Italian study on complications of oral anticoagulant therapy. Lancet 1996; 348: 423-428.
10. Garcia DA, Regan S, Crowther M, et al. The risk of hemorrhage among patients with warfarin-associated coagulopathy. J Am Coll Cardiol 2006; 47: 804-808.
11. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019-1026.
12. Clark NP, Witt DM, Delate T, et al. Warfarin-associated research projects and other endeavors consortium. Thromboembolic consequences of subtherapeutic anticoagulation in patients stabilized on warfarin therapy: The low INR study. Pharmacotherapy 2008; 28: 960-967.
13. Dentali F, Riva N, Malato A, et al. Incidence of thromboembolic complications in patients with mechanical heart valves with a subtherapeutic international normalized ratio. J Thorac Cardiovasc Surg 2009; 137: 91-93.
14. Douketis JD, Berger PB, Dunn AS, et al. American college of chest physicians. The perioperative management of antithrombotic therapy: American college of chest physicians evidence-based clinical practice guidelines (8th ed). Chest 2008; 133(6 Suppl): 299S-339S.
15. Ferreira I, Dos L, Tornos P, et al. Experience with enoxaparin in patients with mechanical heart valves who must withhold acenocumarol. Heart 2003; 89: 527-530.
16. Hammerstingl C, Tripp C, Schmidt H, et al. Periprocedural bridging therapy with low-molecular-weight heparin in chronically anticoagulated patients with prosthetic mechanical heart valves: Experience in 116 patients from the prospective BRAVE registry. J Heart Valve Dis 2007; 16: 285-292.
17. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870.
18. Rose AJ, Ozonoff A, Grant RW, et al. Epidemiology of subtherapeutic anticoagulation in the United States. Circ Cardiovasc Qual Outcomes 2009; 2: 591-597.
19. Rombouts E, Rosendaal FR, Van der Meer FJ. Subtherapeutic oral anticoagulant therapy: Frequency and risk factors. Thromb Hemost 2009; 101: 552-556.
20. Palareti G, Manotti C, DAngelo A, et al. Thrombotic events during oral anticoagulant treatment: Results of the inception-cohort, prospective, collaborative ISCOAT study: ISCOAT study group (Italian study on complications of oral anticoagulant therapy). Thromb Hemost 1997; 78: 1438-1443.